年龄对B细胞急性淋巴细胞白血病药物基因组学及治疗结局的影响
该研究纳入767例儿童和309例成人新诊断B细胞急性淋巴细胞白血病患者,检测白血病细胞对21种药物的体外敏感性并鉴定23种分子亚型。7种药物在儿童与成人间活性不同,其中6种可由年龄相关分子亚型差异解释;部分儿童虽为儿童年龄但白血病基因表达呈成人样,预后差。
要点
- 7种ALL药物在儿童与成人间体外活性不同,其中6种由年龄相关分子亚型差异解释。
- 巯嘌呤在儿童中表现出不依赖亚型的更高敏感性。
- 部分儿童虽为儿童年龄但白血病基因表达呈成人样,预后差。
核心结论
- 研究提供药物基因组学见解解释ALL治愈率的年龄差异,并鉴定可用于跨年龄组治疗个体化的白血病预后特征。
研究设计与样本
- 研究纳入在St Jude儿童研究医院、MD Anderson癌症中心、肿瘤临床试验联盟和ECOG-ACRIN癌症研究组一线试验中入组的767例儿童和309例成人新诊断B细胞ALL患者。
- 检测白血病细胞对21种药物的体外敏感性,并使用RNA测序鉴定23种ALL分子亚型。
主要发现
- 7种ALL药物(天冬酰胺酶、泼尼松龙、巯嘌呤、达沙替尼、奈拉滨、柔红霉素和奥加伊妥珠单抗)在儿童与成人间显示差异活性,其中6种由年龄相关白血病分子亚型差异解释。
- 相对于低龄儿童,青少年和年轻成人表现出与老年人相似的耐药模式。
- 巯嘌呤在儿童中表现出不依赖亚型的更高敏感性。
- 转录组分析发现CRLF2重排、DUX4重排和KMT2A重排ALL内与年龄和细胞毒性药物耐药相关的亚簇。
- 部分儿童基于跨亚型白血病基因表达模式呈现成人样ALL,尽管其实际年龄为儿童;这些对细胞毒性药物耐药的成人样ALL儿童在儿童ALL试验中预后差,即使调整年龄和微小残留病后仍如此。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Acute lymphoblastic leukemia (ALL) can occur across all age groups, with a strikingly higher cure rate in children compared with adults. However, the pharmacological basis of age-related differences in ALL treatment response remains unclear. METHODS: Studying 767 children and 309 adults with newly diagnosed B-cell ALL enrolled on frontline trials at St Jude Children's Research Hospital, MD Anderson Cancer Center, the Alliance for Clinical Trials in Oncology, and the ECOG-ACRIN Cancer Research Group, we determined the ex vivo sensitivity of leukemia cells to 21 drugs. Twenty-three ALL molecular subtypes were identified using RNA sequencing. We systematically characterized the associations between drug response and ALL genomics in children, adolescents and young adults, and elderly adults. We evaluated the effect of age-related gene expression signature on ALL treatment outcomes. RESULTS: Seven ALL drugs (asparaginase, prednisolone, mercaptopurine, dasatinib, nelarabine, daunorubicin, and inotuzumab ozogamicin) showed differential activity between children and adults, of which six were explained by age-related differences in leukemia molecular subtypes. Adolescents and young adults showed similar patterns of drug resistance as older adults, relative to young children. Mercaptopurine exhibited subtype-independent greater sensitivity in children. Transcriptomic profiling uncovered subclusters within CRLF2-, DUX4-, and KMT2A-rearranged ALL that were linked to age and cytotoxic drug resistance. In particular, a subset of children had adult-like ALL on the basis of leukemia gene expression patterns across subtypes, despite their chronological age. Resistant to cytotoxic drugs, children with adult-like ALL exhibited poor prognosis in pediatric ALL trials, even after adjusting for age and minimal residual diseases. CONCLUSION: Our results provide pharmacogenomic insights into age-related disparities in ALL cure rates and identify leukemia prognostic features for treatment individualization across age groups.
引用
- Yoshimura S, Li Z, Gocho Y, et al. Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2024. PMID: 39102629. doi:10.1200/JCO.24.00500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。